title: The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.
abstract: BACKGROUND
  Onychomycosis is a fungal infection of the nail apparatus that can be challenging to treat due to the modest efficacy of existing antifungal therapies and a high rate of relapse and recurrence.
  
  
  OBJECTIVE
  To investigate the efficacy and safety of efinaconazole 10% solution in pooled Phase III clinical trial participants with mild to moderate onychomycosis.
  
  
  METHODS
  Phase III clinical trials data from NCT01008033 and NCT01007708 were pooled. Efficacy analysis for the primary and secondary outcome variables was conducted using the mITT population and analysed using Cochran-Mantel-Haenszel tests. Subgroup analysis was conducted for prognostic factors that may affect drug efficacy. Safety analysis was conducted on all recipients of a single drug dose.
  
  
  RESULTS
  Efinaconazole 10% nail solution was superior to vehicle for all primary and secondary outcome measures assessed. Complete cure was 18.5% vs 4.7% P< 0.001 [mITT] and mycological cure was 56.3% vs 16.6%, P< 0.001 [mITT]. Complete or almost complete cure and treatment success were achieved in 27.7% and 47.2% compared to 7.9% and 18.2% with vehicle, respectively (P< 0.001 [mITT]). In all subgroups, efinaconazole 10% solution had statistically higher cures rates compared to vehicle. Higher complete cure rates were observed in women and individuals with mild disease (≤33% involvement), but not in any other subgroup assessed. Treatment associated adverse events in the efinaconazole 10% solution group were similar to vehicle and limited to local site reactions (2%).
  
  
  CONCLUSIONS
  The findings from this pooled analysis suggest that efinaconazole 10% solution may become the preferred topical agent for mild to moderate onychomycosis.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Boni E
authors.initials: BE
authors.lastname: Elewski
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Sugarman
authors.forename: Chikara
authors.initials: C
authors.lastname: Ieda
authors.forename: Hideki
authors.initials: H
authors.lastname: Kawabata
authors.forename: Robert
authors.initials: R
authors.lastname: Kang
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Pillai
authors.forename: Jason T
authors.initials: JT
authors.lastname: Olin
authors.forename: Shinichi
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy*; D019999:Pharmaceutical Solutions; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D019999:Pharmaceutical Solutions; D014230:Triazoles; C431707:efinaconazole